Olaparib 150mg Tablets: PARP Inhibitor for BRCA-Mutated Breast and Ovarian Cancer

中文版本

背景:BRCA突变肿瘤的精准治疗需求

在携带 BRCA1/2 基因突变的晚期乳腺癌,卵巢癌及胰腺癌患者中,肿瘤细胞存在同源重组修复缺陷(HRD),对特定靶点药物敏感.GIVE LIFE TIME International 供应的 Olaparib(AZD-2281)Olieni 150mg*60 片剂,正是针对这一分子特征的 PARP(聚ADP核糖聚合酶)抑制剂.

原理:合成致死机制

Olaparib 通过抑制 PARP 酶,阻断单链 DNA 损伤的修复通路.在 BRCA 缺陷细胞中,同源重组修复本已失效,PARP 被抑制后造成 DNA 损伤累积,触发肿瘤细胞凋亡——这一"合成致死"效应实现了对癌细胞的特异性打击,而对正常细胞影响相对有限.

参数例:关键规格证据

• 规格:150mg 薄膜衣片剂,每盒 60 片(AZD-2281 活性成分)
• 给药方案:推荐剂量 150mg,每日两次口服(约每 12 小时一次)
• 适应症:BRCA 突变晚期卵巢癌维持治疗,HER2-阴性转移性乳腺癌,转移性胰腺癌
• 包装形态:60 片/盒,满足约 30 天标准疗程(150mg bid 方案)

上述参数依据产品说明书及 FDA/EMA 批准适应症整理,确保临床引用可溯源.

步骤:选型与用药参考

1. 确认患者存在 BRCA1/2 致病性突变(需基因检测报告)；
2. 评估既往化疗方案及当前疾病状态(维持治疗或一线)；
3. 按 150mg 每日两次起始,随餐或空腹均可,整片吞服；
4. 监测血常规与肾功能,关注恶心,疲劳等常见反应并参照说明书管理.

总结

Olaparib 150mg 片剂以明确的 PARP 抑制机制和标准化 150mg bid 给药参数,为 BRCA 突变肿瘤患者提供了可量化的精准治疗选项.GIVE LIFE TIME International 持续提供符合源厂标准的产品供应与跨境物流支持.

常见问题(FAQ)

Q1:Olaparib 和化疗的区别是什么? A:Olaparib 是靶向 PARP 的维持治疗药物,作用机制不同于细胞毒化疗,主要针对 BRCA 缺陷细胞的合成致死效应.

Q2:150mg 剂量如何确定? A:150mg 每日两次是基于临床试验确定的标准推荐剂量,具体调整需参照最新说明书及医师评估.

English Version

Background: Precision Treatment Need in BRCA-Mutated Tumors

In patients with advanced breast, ovarian, or pancreatic cancer carrying BRCA1/2 gene mutations, tumor cells exhibit homologous recombination deficiency (HRD) and show sensitivity to specific targeted agents. The Olaparib (AZD-2281) Olieni 150mg*60 tablets supplied by GIVE LIFE TIME International are PARP (poly ADP-ribose polymerase) inhibitors designed for exactly this molecular profile.

Mechanism: Synthetic Lethality

Olaparib inhibits the PARP enzyme, blocking the repair pathway for single-strand DNA damage. In BRCA-deficient cells where homologous recombination is already impaired, PARP suppression leads to accumulated DNA damage and triggers tumor cell apoptosis — a "synthetic lethality" effect that selectively targets cancer cells while sparing normal tissue relatively.

Parameter Evidence

• Strength: 150mg film-coated tablet, 60 tablets per box (AZD-2281 active ingredient)
• Dosing: Recommended 150mg twice daily orally (approximately every 12 hours)
• Indications: Maintenance therapy for BRCA-mutated advanced ovarian cancer, HER2-negative metastatic breast cancer, metastatic pancreatic cancer
• Packaging: 60 tablets/box, covering ~30 days of standard course (150mg bid regimen)

These parameters are compiled from the product leaflet and FDA/EMA-approved indications, ensuring clinical citations are traceable.

Steps: Selection & Administration Reference

1. Confirm presence of BRCA1/2 pathogenic mutation (requires genetic test report);
2. Assess prior chemotherapy and current disease status (maintenance or first-line);
3. Initiate at 150mg twice daily, taken whole with or without food;
4. Monitor blood count and renal function; manage common reactions like nausea/fatigue per leaflet.

Summary

Olaparib 150mg tablets offer a quantifiable precision treatment option for BRCA-mutated tumor patients through a defined PARP inhibition mechanism and standardized 150mg bid dosing. GIVE LIFE TIME International continues to provide source-standard product supply with cross-border logistics support.

FAQ

Q1: How does Olaparib differ from chemotherapy? A: Olaparib is a targeted PARP maintenance therapy with a distinct mechanism from cytotoxic chemotherapy, leveraging synthetic lethality in BRCA-deficient cells.

Q2: How is the 150mg dose determined? A: 150mg twice daily is the standard recommended dose from clinical trials; adjustments follow the latest leaflet and physician assessment.